Chemotherapy before surgery vs. surgery alone for left-sided pancreatic cancer
Part of Cancer clinical trials.
This trial is for people with left-sided pancreatic cancer that can be removed by surgery. It compares starting with chemotherapy before surgery versus going straight to surgery, to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with left-sided pancreatic cancer that can be removed with surgery (resectable).
- You are 18 years or older.
- You are able to give informed consent after understanding the study details.
- You are generally healthy enough to undergo surgery and chemotherapy (ECOG score 0–2).
- Your cancer type is ductal adenocarcinoma (the most common type of pancreatic cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial tests 6 cycles of a chemotherapy combination called modified FOLFIRINOX before surgery for pancreatic cancer that can potentially be removed. The goal is to see if this approach improves outcomes for patients who might be candidates for another study called PANACHE02.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests a three-drug chemotherapy combination (gemcitabine, cisplatin, and nab-paclitaxel) given before surgery for people with pancreatic cancer that can be removed or is on the edge of being removable. The goal is to shrink the tumor and improve surgery outcomes.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.